Viral safety of plasma-derived medicinal products needs to be kept under review as viruses are identified that can be present in the plasma starting material. Initiating action with a workshop will provide an effective means of bringing together and discussing the currently available information on this topic. This will then allow further actions to be identified.

 

Posted on the EMA website on 2 May 2014